Lulutox Detox Tea officially launches across Ireland, the USA, UK, Australia and Canada. Formulated with natural herbs like ...

D-Bal – Mimicking the effects of Dianabol, D-Bal boosts nitrogen retention and protein synthesis for rapid muscle growth.

Hapbee Technologies Inc. (TSXV: HAPB | OTCQB: HAPBF), (“Hapbee” or the “Company”), the digital wellness technology company pioneering the science of bio-streaming, announced today its operational and ...

“Exosomes offer exciting possibilities as cell-free tools in regenerative medicine,” said Dr. Ruby Tsai, CEO of Applied StemCell. “Our hiEX™ iPSC Exosomes give researchers a dependable and ...

CROSSJECT announces a successful capital increase of €5.7 million following full exercise of the extension clause En cliquant sur ce lien, vous acceptez l'utilisation de cookies sur ce site internet.

The 18-month study, initiated in 2022 and completed in late 2023, leveraged Inventprise’s proprietary linker protein conjugation technology platform. This advanced technology is designed to enhance ...

Paris, le 24 juin 2025 – Clariane (CLARI.PA – ISIN FR0010386334), annonce aujourd’hui avoir placé avec succès une émission obligataire non-sécurisée d’un montant total de 400 millions d’euros à ...

GN Store Nord A/S hereby announces that on June 23, 2025, pursuant to Section 38 (1) and Section 39 (1) of the Danish Capital Markets Act, it received a notification from BlackRock, Inc. stating that ...

La maladie d’Alzheimer touche près d’un million de personnes en France, avec environ 225.000 nouveaux cas diagnostiqués ...

Zarminali Pediatrics, the first outpatient pediatric destination purpose-built to provide elevated, seamlessly coordinated primary and specialty care nationwide, announced that Green Tree Pediatrics ...

Priothera Secures €1.7 million i-Nov Funding by Bpifrance for Rare Blood Cancer Clinical Program Funding to support MOCART, a clinical programme evaluating mocravimod added to standard CAR-T cell ...

Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced cancer and autoimmune disease, today announced that the Company completed the second closing ...